Literature DB >> 31667551

[Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: HYPO-RT-PC randomized trial. 5-year results: Commentary II].

Gregor Goldner1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31667551     DOI： 10.1007/s00066-019-01536-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

Authors:  Charles N Catton; Himu Lukka; Chu-Shu Gu; Jarad M Martin; Stéphane Supiot; Peter W M Chung; Glenn S Bauman; Jean-Paul Bahary; Shahida Ahmed; Patrick Cheung; Keen Hun Tai; Jackson S Wu; Matthew B Parliament; Theodoros Tsakiridis; Tom B Corbett; Colin Tang; Ian S Dayes; Padraig Warde; Tim K Craig; Jim A Julian; Mark N Levine
Journal:  J Clin Oncol       Date:  2017-03-15       Impact factor: 44.544

2.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.

Authors:  Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler
Journal:  J Urol       Date:  2019-03       Impact factor: 7.450

3.  Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Authors:  Luca Incrocci; Ruud C Wortel; Wendimagegn Ghidey Alemayehu; Shafak Aluwini; Erik Schimmel; Stijn Krol; Peter-Paul van der Toorn; Hanja de Jager; Wilma Heemsbergen; Ben Heijmen; Floris Pos
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

4.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316
  4 in total
  1 in total

Review 1.  Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.

Authors:  Frank Wolf; Felix Sedlmayer; Daniel Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Pirus Ghadjar; Stefan Höcht; Tobias Hölscher; Arndt-Christian Müller; Peter Niehoff; Michael Pinkawa; Nina-Sophie Schmidt-Hegemann; Constantinos Zamboglou; Daniel Zips; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2020-12-10       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.